MedLife invests EUR 3 million in genetic testing, becoming a leader in personalized medicine in Romania with the aim to improve quality of life.

MedLife is to launch an innovative genetic testing program, with an initial investment of €3 million, aimed at facilitating access to individual genetic mapping and promoting personalized medicine. The project will involve over 4,000 beneficiaries and will use Illumina NovaSeq X Plus sequencing technology, one of the most advanced in the world. This initiative marks an important transition in the Romanian medical system, aiming at prevention and personalization of treatments according to genetic profile. MedLife, with more than 20 years of experience in genetics, thus confirms its leading role in the field and its commitment to improve the health of the population.